COVISHIELD VACCINE MAYBE RECOMMENDED FOR INTERNATIONAL USE

HIGHLIGHTS

• AstraZeneca is in talks with governments of many countries.
• AstraZeneca is also engaging with multilateral organizations and many other partners around the world.
• AstraZeneca wants broad and equitable access to the vaccine for ev...

SII RELEASES FAQ FACTSHEET FOR COVISHIELD VACCINE

HIGHLIGHTS

• SII has released FAQ Factsheet for Covishield Vaccine.
• The new factsheet details information for vaccine recipients regarding the benefits and common side-effects of the Covishield vaccine.
• The Covishield has been approved for re...

SERUM INSTITUTE CEO WARNS OF COVID-19 VACCINE SHORTAGE TILL 2024

HIGHLIGHTS

• Serum Institute CEO says that till 2024, coronavirus vaccine availability will not be enough.
• Two doses of vaccine are required to create immunity against coronavirus.

On Monday, 14 SEP 2020, Adar Poonawalla, the CEO of Se...

COVID-19 VACCINE: SERUM INSTITUTE OF INDIA TO COMMENCE PHASE II TRIAL OF OXFORD VACCINE TODAY

According to the sources, the phase II human clinical trial of the Oxford COVID-19 vaccine candidate by the Serum Institute of India (SII), Pune will start from today. Bharati Vidyapeeth Medical College and Hospital in Pune is the site where this observer-blind, randomised controlled study to det...

NOVAVAX, SERUM INSTITUTE OF INDIA JOIN HANDS TO SUPPLY COVID-19 VACCINE

Highlights

• The Serum Institute of India will have exclusive rights for the COVID-19 vaccine in India and non-exclusive rights during the pandemic period in all countries except those designated as upper-middle or high-income nations

• The COVID-19 vaccine developed...

COVID-19 VACCINE: DCGI APPROVES PHASE 2 AND 3 CLINICAL TRIALS OF OXFORD VACCINE BY SERUM INSTITUTE

Highlights

• DCGI Dr V G Somani granted approval for conducting phase 2 and 3 human clinical trials by the SII

• ‘Covishield’ a potential vaccine for COVID-19 has been developed by the University of Oxford

• Before starting the phase 3 tria...